Search

Your search keyword '"Altorki, N."' showing total 337 results
Start Over Author "Altorki, N."
337 results on '"Altorki, N."'

2. MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

Author

Felip, E., primary, Srivastava, M., additional, Reck, M., additional, Wakelee, H., additional, Altorki, N., additional, Vallieres, E., additional, Liersch, R., additional, Oizumi, S., additional, Tanaka, H., additional, Hamm, J.T., additional, Novello, S., additional, McCune, S., additional, Molinero, L., additional, McNally, V., additional, Morris, S., additional, Ballinger, M., additional, Li, H., additional, Zou, W., additional, Nabet, B.J., additional, Bennett, E., additional, Gitlitz, B.J., additional, and Zhou, C., additional

Published
2023
Full Text
View/download PDF

9. PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

Author

Wakelee, H., primary, Altorki, N., additional, Felip, E., additional, Vallieres, E., additional, Vynnychenko, I.O., additional, Akopov, A., additional, Martinez-Marti, A., additional, Chella, A., additional, Bondarenko, I., additional, Sugawara, S., additional, Fan, Y., additional, Kenmotsu, H., additional, Chen, Y.-M., additional, Deng, Y., additional, Wu, F., additional, McNally, V., additional, Bennett, E., additional, Gitlitz, B.J., additional, and Zhou, C., additional

Published
2022
Full Text
View/download PDF

14. PL02.05 IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

Author

Altorki, N., primary, Felip, E., additional, Zhou, C., additional, Vallieres, E., additional, Moiseyenko, V., additional, Smolin, A., additional, Rittmeyer, A., additional, Vereshchako, R., additional, Perol, M., additional, Schutte, W., additional, Fang, J., additional, Tao, M., additional, Teixeira, E., additional, Kim, Y., additional, Gitlitz, B., additional, Bennett, E., additional, Mcnally, V., additional, Wu, F., additional, Deng, Y., additional, and Wakelee, H., additional

Published
2021
Full Text
View/download PDF

18. A05 ART1, a Mono-ADP-Ribosyltransferase, Regulates Tumor-Infiltrating CD8+ T Cells and Is Highly Expressed in EGFR Mutated Lung Cancers

Author

Mukherjee, S., primary, Wennerberg, E., additional, Hung, C., additional, Saadallah, N., additional, Kariyawasam, S., additional, Hussein, M.K., additional, Narula, N., additional, Adusumilli, P., additional, Borczuk, A., additional, Altorki, N., additional, McGraw, T., additional, and Stiles, B.M., additional

Published
2020
Full Text
View/download PDF

26. P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)

Author

Altorki, N., primary, Borczuk, A., additional, Saxena, A., additional, Port, J., additional, Stiles, B., additional, Lee, B., additional, Sanfilippo, N., additional, Ko, E., additional, Scheff, R., additional, Pua, B., additional, Gruden, J., additional, Christos, P., additional, Spinelli, C., additional, Gakuria, J., additional, Mittal, V., additional, Mcgraw, T., additional, and Formenti, S., additional

Published
2019
Full Text
View/download PDF

27. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors

Author

Okuma, Y, Horio, H, Matsumura, A, Higashiyama, M, Suehisa, H, Onuki, T, Sano, Y, Kondo, K, Al Kattan, K, Cerfolio, R, Gebitekin, C, de Antonio, D, Kernstine, Kh, Altorki, N, Novoa, N, Ruffini, E, Filosso, Pl, Saita, S, Scarci, M, Voltolini, L, Weder, W, Zurek, W, Arame, A, Casadio, C, Carbognani, P, Donati, G, Keshavjee, S, Klepetko, W, Moser, B, Lequaglie, C, Liberman, M, Mancuso, M, Nosotti, M, Spaggiari, L, Thomas, Pa, Rendina, Erino Angelo, Venuta, Federico, Anile, Marco, Schützner, J, Rocco, G., Staging Prognostic Factors Comm, Advisory Boards, Participating Inst Thymic Domain, University of Zurich, and Detterbeck, Frank C

Subjects
Humans, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Prognosis, Thymus Neoplasms, Pulmonary and Respiratory Medicine, Stage classification, Lymphatic metastasis, medicine.medical_specialty, Pathology, Staging, Thymoma, 10255 Clinic for Thoracic Surgery, 610 Medicine & health, M Components, Thymic carcinoma, Neoplasms, medicine, Survival analysis, Nodal involvement, business.industry, Glandular and Epithelial, Cancer, medicine.disease, Oncology, 2740 Pulmonary and Respiratory Medicine, 2730 Oncology, Human medicine, Radiology, business
Abstract

Despite longstanding recognition of thymic epithelial neoplasms, there is no official American Joint Committee on Cancer/Union for International Cancer Control stage classification. This article summarizes proposals for classification of the T component of stage classification for use in the 8th edition of the tumor, node, metastasis classification for malignant tumors. This represents the output of the International Association for the Study of Lung Cancer and the International Thymic Malignancies Interest Group Staging and Prognostics Factor Committee, which assembled and analyzed a worldwide database of 10,808 patients with thymic malignancies from 105 sites. The committee proposes division of the T component into four categories, representing levels of invasion. T1 includes tumors localized to the thymus and anterior mediastinal fat, regardless of capsular invasion, up to and including infiltration through the mediastinal pleura. Invasion of the pericardium is designated as T2. T3 includes tumors with direct involvement of a group of mediastinal structures either singly or in combination: lung, brachiocephalic vein, superior vena cava, chest wall, and phrenic nerve. Invasion of more central structures constitutes T4: aorta and arch vessels, intrapericardial pulmonary artery, myocardium, trachea, and esophagus. Size did not emerge as a useful descriptor for stage classification. This classification of T categories, combined with a classification of N and M categories, provides a basis for a robust tumor, node, metastasis classification system for the 8th edition of American Joint Committee on Cancer/Union for International Cancer Control stage classification.

Published
2014

38. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors

Author

Rosenberg, M, Tomulescu, V, Huang, J, Foroulis, C, Lang Lazdunski, L, Billè, A, Maessen, Jg, Keijzers, M, van Veer, H, Wright, C, Marino, M, Facciolo, F, Palmieri, G, Buonerba, C, Ferguson, M, Marulli, G, Lucchi, M, Loehrer, P, Kalkat, M, Rohrberg, K, Daugaard, G, Toker, A, Erus, S, Kimmich, M, Brunelli, A, Refai, M, Nicholson, A, Lim, E, Park, Ik, Wagner, J, Tieu, B, Fang, W, Zhang, J, Yu, Z, Han, Y, Li, Y, Chen, K, Chen, G, Okumura, M, Fujii, Y, Asamura, H, Nagai, K, Nakajima, J, Ikeda, N, Haraguchi, S, Onuki, T, Suzuki, K, Yoshino, I, Tsuchida, M, Takahashi, S, Yokoi, K, Hanyuda, M, Niwa, H, Date, H, Maniwa, Y, Miyoshi, S, Kondo, K, Iwasaki, A, Okamoto, T, Nagayasu, T, Tanaka, F, Suzuki, M, Yoshida, K, Okuma, Y, Horio, H, Matsumura, A, Higashiyama, M, Suehisa, H, Sano, Y, Al Kattan, K, Cerfolio, R, Gebitekin, C, de Antonio, D, Kernstine, Kh, Altorki, N, Novoa, N, Ruffini, E, Filosso, Pl, Saita, S, Scarci, M, Voltolini, L, Weder, W, Zurek, W, Arame, A, Casadio, C, Carbognani, P, Donati, G, Keshavjee, S, Klepetko, W, Moser, B, Lequaglie, C, Liberman, M, Mancuso, M, Nosotti, M, Spaggiari, L, Thomas, Pa, Rendina, Erino Angelo, Venuta, Federico, Anile, Marco, Schützner, J, Rocco, G, Crowley, J, Detterbeck, F, Falkson, C, Filosso, L, Giaccone, G, Giroux, D, Kim, J, Marom, Em, Nicholson, Ag, Brompton, R, Van Schil, P, Stratton, K., University of Zurich, Detterbeck, Frank C, Eberhardt, Wilfried (Beitragende*r), Prognostic Factors Comm, Advisory Boards, and Participating Inst Thymic Domain

Subjects
Pulmonary and Respiratory Medicine, Stage classification, Oncology, medicine.medical_specialty, Pathology, Staging, Thymoma, Evidence-based practice, 10255 Clinic for Thoracic Surgery, Medizin, 610 Medicine & health, Metastasis, Thymic carcinoma, Cohort Studies, Neoplasms, Internal medicine, medicine, Humans, Neoplasms, Glandular and Epithelial, Stage (cooking), Lung cancer, Neoplasm Staging, Retrospective Studies, Evidence-Based Medicine, business.industry, Glandular and Epithelial, Cancer, Thymus Neoplasms, Prognosis, medicine.disease, 2740 Pulmonary and Respiratory Medicine, 2730 Oncology, Human medicine, business
Abstract

A universal and consistent stage classification system, which describes the anatomic extent of a cancer, provides a foundation for communication and collaboration. Thymic epithelial malignancies have seen little progress, in part because of the lack of an official system. The International Association for the Study of Lung Cancer and the International Thymic Malignancies Interest Group assembled a large retrospective database, a multispecialty international committee and carried out extensive analysis to develop proposals for the 8th edition of the stage classification manuals. This tumor, node, metastasis (TNM)-based system is applicable to all types of thymic epithelial malignancies. This article summarizes the proposed definitions of the T, N, and M components and describes how these are combined into stage groups. This represents a major step forward for thymic malignancies.

Published
2014

39. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies

Author

Detterbeck, Fc1, Asamura, H, Crowley, J, Falkson, C, Giaccone, G, Giroux, D, Huang, J, Kim, J, Kondo, K, Lucchi, M, Marino, M, Marom, Em, Nicholson, A, Okumura, M, Ruffini, E, van Schil, P, Stratton, K, Staging, Prognostic Factors Committee, Members of the Advisory Boards, Goldstraw P, Participating Institutions of the Thymic D. o. m. a. i. n., Rami Porta, R, Ball, D, Beer, D, Beyruti, R, Bolejack, V, Chansky, K, Detterbeck, F, Eberhardt, W, Edwards, J, Galateau Sallé, F, Gleeson, F, Groome, P, Kennedy, C, Kim, Y, Kingsbury, L, Kondo, H, Krasnik, M, Kubota, K, Lerut, A, Lyons, G, Marom, E, van Meerbeeck, J, Mitchell, A, Nakano, T, Newman, J, Nowak, A, Peake, M, Rice, T, Rosenzweig, K, Rusch, V, Sculier, Jp, Suzuki, K, Tachimori, Y, Thomas CF Jr, Travis, W, Tsao, M, Turrisi, A, Vansteenkiste, J, Watanabe, H, Wu, Yi, Zielinski, M, Filosso, L, Baas, P, Erasmus, J, Hasegawa, S, Inai, K, Kernstine, K, Kindler, H, Krug, L, Nackaerts, K, Pass, H, Rice, D, Blackstone, E, Call Caja, S, Ahmad, U, Girard, N, Haam, Sj, Bae, Mk, Gomez, Dr, Ströbel, P, Marx, A, Saita, S, Wakelee, H, Bertolaccini, L, Vallieres, E, Scott, W, Su, S, Park, B, Marks, J, Khella, S, Shen, R, Rosenberg, M, Aires, B, Tomulescu, V, Foroulis, C, Lang Lazdunski, L, Billè, A, Maessen, Jg, Keijzers, M, van Veer, H, Wright, C, Palmieri, G, Buonerba, C, Ferguson, M, Marulli, G, Loehrer, P, Kalkat, M, Rohrberg, K, Daugaard, G, Toker, A, Erus, S, Kimmich, M, Brunelli, A, Refai, M, Lim, E, Park, Ik, Wagner, J, Tieu, B, Fang, W, Zhang, J, Yu, Z, Han, Y, Li, Y, Chen, K, Chen, G, Fujii, Y, Nagai, K, Nakajima, J, Ikeda, N, Haraguchi, S, Onuki, T, Yoshino, I, Tsuchida, M, Takahashi, S, Yokoi, K, Hanyuda, M, Niwa, H, Date, H, Maniwa, Y, Miyoshi, S, Iwasaki, A, Okamoto, T, Nagayasu, T, Tanaka, F, Suzuki, M, Yoshida, K, Okuma, Y, Horio, H, Matsumura, A, Higashiyama, M, Suehisa, H, Sano, Y, Kattan, K, Cerfolio, R, Gebitekin, C, de Antonio, D, Kernstine, Kh, Altorki, N, Novoa, N, Filosso, Pl, Scarci, M, Voltolini, L, Weder, W, Zurek, W, Arame, A, Casadio, C, Toracica, C, Carbognani, P, Donati, G, Keshavjee, S, Klepetko, W, Moser, B, Lequaglie, C, Liberman, M, Mancuso, M, Nosotti, M, Spaggiari, L, Thomas, Pa, Rendina, Erino Angelo, Venuta, F, Anile, M, Schützner, J, Rocco, G., Staging Prognostic Factors Comm, University of Zurich, Detterbeck, Frank C, and Eberhardt, Wilfried (Beitragende*r)

Subjects
Pulmonary and Respiratory Medicine, Oncology, Stage classification, medicine.medical_specialty, Pathology, Lung Neoplasms, Thymoma, 10255 Clinic for Thoracic Surgery, Medizin, 610 Medicine & health, Thymic carcinoma, Internal medicine, medicine, Humans, Project management, Program Development, Lung cancer, Neoplasm Staging, business.industry, International Agencies, Thymus Neoplasms, Staging of stage classification, medicine.disease, 2740 Pulmonary and Respiratory Medicine, Interest group, 2730 Oncology, Program development, Human medicine, business
Abstract

The lack of an official-stage classification system for thymic malignancies is an issue that hampers progress in this rare disease. A collaborative effort by the International Association for the Study of Lung Cancer and the International Thymic Malignancies Interest Group is underway to develop proposals for such a system. A database of more than 10,000 cases worldwide has been assembled to provide a solid basis for analysis. This report outlines the structure of the effort and the process that has been designed.

Published
2014

41. Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC) : RADIANT trial

Author

O'Brien, MER, Eberhardt, Wilfried, Altorki, N. K., Spigel, D. R., Crino, L., Tsai, C. M., Cho, E. K., Kim, J. H., Szczesna, A., Hoffman, P. C., Burghuber, O., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Park, J. W., Shepherd, F. A., Kelly, K., and Tarceva Radiant Investigator Grp

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Treatment duration, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), medicine.disease, Placebo, respiratory tract diseases, Surgery, Oncology, medicine, In patient, Erlotinib, business, Adjuvant, medicine.drug
Abstract

7535 Background: We describe treatment duration and safety in the safety full analysis set (sFAS) and in the subset of pts with EGFR del19 and L858R mutations (EGFR M+). Methods: RADIANT was a rand...

Published
2014

42. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC) : RADIANT results

Author

Kelly, K., Altorki, N. K., Eberhardt, Wilfried, O'Brien, MER, Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Park, J. W., Shepherd, F. A., and Tarceva Radiant Investigator Grp

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), medicine.disease, Placebo, Surgery, Internal medicine, medicine, Clinical endpoint, Immunohistochemistry, Adenocarcinoma, Erlotinib, Stage (cooking), business, Adjuvant, medicine.drug
Abstract

7501 Background: The proven efficacy of E in advanced NSCLC warranted its evaluation in the adjuvant setting. BR.21 data suggested pts with EGFR positive tumors (IHC/FISH) were more likely to benefit from E. Methods: Completely resected IB-IIIA NSCLC pts were randomized 2:1 to receive E 150 mg qd or P for 2 years. Pts were stratified according to stage, histology, prior adjuvant chemotherapy, smoking status, EGFR FISH status, and country. The primary endpoint was disease free survival (DFS) in the full analysis set (FAS). Secondary endpoints included overall survival (OS) in the FAS and DFS and OS in the EGFR mutation (EGFR M+) subset (del19/L858R). Hierarchical testing procedure was used. Results: Between NOV 2007 and JUL 2010, 973 pts were randomized. Baseline characteristics were balanced between arms (age > 65 41%; female 41%; stage IB 51%, II 33%, IIIA 16% [AJCC 6th ed]; adenocarcinoma 59%; prior adjuvant chemotherapy 53%; never smoker 20%; Asian 17%; EGFR FISH+ 72% and EGFR M+ 16.5%). The planned nu...

Published
2014

43. Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial

Author

Shepherd, F. A., Altorki, N. K., Eberhardt, Wilfried, O'Brien, Mary, Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Richardson, F. C., Kelly, K., and Tarceva Radiant Investigator Grp

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), macromolecular substances, Placebo, medicine.disease, respiratory tract diseases, carbohydrates (lipids), stomatognathic diseases, Exon, Egfr tki, Internal medicine, Immunology, otorhinolaryngologic diseases, medicine, Erlotinib, business, Adjuvant, medicine.drug
Abstract

7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts with tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to EGFR TKIs. Methods: RADIA...

Published
2014

47. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

Author

Wilbertz, T, Wagner, P, Petersen, K, Stiedl, A C, Scheble, V J, Maier, S, Reischl, M, Mikut, R, Altorki, N K, Moch, H, Fend, F, Staebler, A, Bass, A J, Meyerson, M, Rubin, M A, Soltermann, A, Lengerke, C, Perner, S, University of Zurich, and Perner, S

Subjects
2734 Pathology and Forensic Medicine, 10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health
Published
2011

50. GENDER DIFFERENCES IN LUNG CANCERS DETECTED ON CT IN AN ANNUAL SCREENING PROGRAM FOR LUNG CANCER

Author

Henschke, C I., Buckshee, Natasha, McCauley, D, Yankelevitz, D, Naidich, D, McGuinness, G, Miettinen, O S., Libby, Daniel, Pasmantier, M, Koizumi, J, Altorki, N, and Smith, J P.

Subjects
Sex factors in disease -- Health aspects -- Risk factors, Lung cancer -- Risk factors -- Health aspects, Health, Risk factors, Health aspects
Abstract

Purpose: To assess the relative risk (RR) of lung cancer among high-risk women and men enrolled in the Early Lung Cancer Action Program (ELCAP), an annual CT screening program. Methods: [...]

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results